Mycosyst (Fluconazole)

Fluconazole, the active ingredient in Mycosyst, is an azole antifungal presented as an oral dosage form for systemic use. It treats a range of fungal infections, including candidiasis, cryptococcal meningitis and other systemic mycoses, in adult and pediatric patients as prescribed by a healthcare professional.

GNH USA supplies Mycosyst as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Fluconazole acts on a broad spectrum of fungal pathogens, making Mycosyst suitable for several serious infections. - Candidiasis: effective for oral, esophageal, vaginal and systemic infections caused by Candida species. - Cryptococcal meningitis: used in induction and consolidation therapy for central nervous system infection. - Systemic fungal infections: treats invasive infections such as blastomycosis, histoplasmosis and coccidioidomycosis when other agents are unsuitable.

Fluconazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the abdomen. - Diarrhea: loose stools. - Rash: skin redness or itching. - Elevated liver enzymes: mild hepatic enzyme changes.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Anaphylaxis: rare but life‑threatening allergic response. - QT interval prolongation: potential cardiac rhythm disturbance. - Severe neutropenia: marked reduction in white blood cells. - Hepatic failure: rare but critical liver dysfunction.

Before initiating therapy with Mycosyst, consider the following safety measures. - Assess liver function: obtain baseline liver enzymes and monitor periodically. - Review concomitant medications: identify potential drug‑drug interactions. - Evaluate renal function: dose adjustment may be needed in severe impairment. - Pregnancy and lactation: use only if benefits outweigh potential risks, as data are limited. - Known hypersensitivity: avoid in patients with documented allergy to fluconazole or other azoles. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Fluconazole can alter the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Rifampin: induces metabolism, markedly reducing fluconazole exposure. - Terbinafine: combined use increases risk of hepatotoxicity. - Certain azole combinations: additive toxicity may occur.

Moderate Interactions (Monitor Closely): - Warfarin: fluconazole may increase INR, requiring dose adjustment. - Phenytoin: may decrease fluconazole levels, reducing efficacy. - Oral contraceptives: possible reduction in contraceptive effectiveness. - Cyclosporine or tacrolimus: may increase levels, necessitating monitoring. - Statins (e.g., simvastatin): increased risk of myopathy, monitor for muscle symptoms.